Digital engagement is becoming the new normal, but it can inhibit the individual connection that is foundational to building long-term customer relationships. How can reps, brand teams, and medical science liaisons strike the right balance of personal and non-personal engagement? The next generation of AI has an answer, writes Derek Choy.
Pharma marketers can use their "voice" to increase prominence in advertising.
Lise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.
The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.
Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.
Technology has potential to change how physicians work with asthma patients
A look at how UCB is utilizing dynamic targeting via AI to improve overall patient experience.
Pharma companies are struggling to maintain a high level of cybersecurity amidst the pandemic.
As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.
Peter Kohut analyses the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.
The recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.
Their application for security and anti-counterfeiting purposes continues to evolve, especially in combination with digital technology.
When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.
How companies are leveraging Real Word Evidence to evaluate therapies under real world conditions in a broader population at a lower cost than using Randomized Clinical Trials.
A new patient journey is emerging. Gilda Sala, Trista Bridges, and Rune Soelvsteen offer easy steps to future-proof your company’s approach.
Stephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.
Priyanka Chaudhary and Vikram Shetty outline the current challenges and opportunities presented by e-labeling around the world.
Xavier Duburcq describes how pharma leaders can convert compliance from a cost center to a critical success factor.
A crisis like COVID-19 is not one event, but many interconnected crises. If we’re not constantly learning and adapting, we’re going to be facing a long, painful recovery. We need to modernize how we operate, writes Derek Choy.
With medical meetings and congresses going virtual in the face of COVID-19, how do pharma companies put together a strategic plan for a new format that meets goals while remaining sensitive to the broader environment?
Hunting for effective treatments, tools offer support in global fight.
Pharma companies may be in a unique position to support at-risk patients with chronic illnesses at this unusual time, particularly if they already have patient support programs in place with a patient services hub, writes Rebecca Cotton.
The need for analytics translators is not limited to data science. The adoption of all scientific or technical advances, including those in the healthcare industry, needs effective translators. So what does this mean for pharma marketing?
A centralized platform for assets supports the industry’s need for a greater volume of more diverse content, writes Callum Hawes.
